DMAC · XBRL financial data

DiaMedica Therapeutics financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (DMAC's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Research and development	3,272	3,677*	3,676	3,928	4,983	6,470*	5,656	5,822	6,437	6,699*	7,987	8,153
General and administrative	1,885	2,171*	2,065	1,710	1,900	1,949*	2,488	2,185	2,596	2,514*	2,495	2,345
Total operating expenses	—	year only	—	—	—	year only	—	—	—	year only	—	—
Operating income (loss)	(5,157)	(5,848)*	(5,741)	(5,638)	(6,883)	(8,419)*	(8,144)	(8,007)	(9,033)	(9,213)*	(10,482)	(10,498)
Interest income	—	year only	616	524	618	543*	444	313	440	472*	470	—
Other income (expense)	693	709*	597	526	616	528*	443	1	(21)	1,680*	447	366
Income tax expense (benefit)	7	22*	7	7	7	9*	6	6	6	10*	7	7
Net income (loss)	(4,471)	(5,161)*	(5,151)	(5,119)	(6,274)	(7,900)*	(7,707)	(7,699)	(8,620)	(8,740)*	(10,042)	(10,139)
Earnings per share, basic USD per share	(0.12)	(0.13)*	(0.14)	(0.13)	(0.15)	(0.18)*	(0.18)	(0.18)	(0.17)	(0.17)*	(0.19)	(0.19)
Weighted average shares, basic thousands of shares	37,949	38,366*	37,958	38,068	42,752	42,789*	42,844	42,958	49,630	52,358*	53,793	53,894

Balance sheet

CSV

Fiscal quarters (DMAC's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	2,232	4,543	2,097	14,066	4,134	3,025	2,589	4,109	3,326	15,647	4,868	5,129
Marketable securities	44,233	48,352	44,419	39,989	46,063	41,122	33,731	25,929	51,992	44,243	46,463	38,375
Marketable securities, non-current	9,746	—	—	—	—	0	1,000	—	—	—	—	—
Accounts receivable	310	369	399	391	290	236	253	161	260	258	301	244
Prepaid and other current assets	1,111	411	569	568	280	227	649	680	445	481	731	567
Total current assets	47,886	53,675	47,484	55,014	50,767	44,610	37,422	31,079	56,223	60,629	52,363	44,315
Property and equipment, net	135	131	132	152	151	148	149	152	150	145	142	133
Right-of-use asset	372	354	336	317	298	279	259	239	218	197	175	153
Total assets	58,139	54,160	49,260	56,791	52,524	46,345	38,830	31,470	57,047	61,371	53,080	45,001
Accounts payable	863	926	716	759	1,171	940	1,507	1,261	1,920	1,475	3,293	2,812
Accrued liabilities	1,227	1,777	1,815	2,229	3,024	4,347	3,053	2,747	3,239	3,545	2,340	3,666
Total current liabilities	2,170	2,786	2,617	3,088	4,297	5,390	4,665	4,116	5,268	5,132	5,748	6,594
Lease liability, non-current	337	316	294	272	249	225	201	176	150	124	96	69
Accumulated deficit	(110,397)	(115,558)	(120,709)	(125,828)	(132,102)	(140,002)	(147,709)	(155,408)	(164,028)	(172,768)	(182,810)	(192,949)
Total stockholders' equity	55,629	51,057	46,349	53,415	47,964	40,718	33,954	27,170	51,622	56,111	47,235	38,338
Total liabilities and equity	58,139	54,160	49,260	56,791	52,524	46,345	38,830	31,470	57,047	61,371	53,080	45,001
Common shares outstanding (cover page) thousands of shares	37,954	37,958	37,964	42,748	42,761	42,856	42,883	51,689	52,077	53,883	53,883	53,926

Cash flows

CSV

Fiscal quarters (DMAC's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	(4,471)	(5,161)*	(5,151)	(5,119)	(6,274)	(7,900)*	(7,707)	(7,699)	(8,620)	(8,740)*	(10,042)	(10,139)
Stock-based compensation	425*	456*	488	443*	565*	589*	867	771*	1,016*	1,192*	822	1,118*
Net cash from operating activities	(4,797)*	(3,812)*	(6,653)	(4,519)*	(4,470)*	(6,434)*	(7,149)	(7,598)*	(6,550)*	(7,765)*	(9,082)	(8,114)*
Purchases of property and equipment	10*	3*	9	0*	9*	7*	12	6*	16*	6*	8	3*
Net cash from investing activities	1,196*	6,124*	4,208	4,736*	(5,585)*	5,205*	6,622	8,957*	(25,766)*	7,995*	(2,114)	8,243*
Proceeds from issuing common stock	(4)*	0*	—	—	0*	0*	—	—	31,527*	11,755*	—	—
Net cash from financing activities	(6)*	(1)*	(1)	11,752*	123*	120*	91	161*	31,533*	12,091*	417	132*
Net change in cash	(3,607)*	2,311*	(2,446)	11,969*	(9,932)*	(1,109)*	(436)	1,520*	(783)*	12,321*	(10,779)	261*

Compare with peers

The peer list for this company is being put together from its industry's latest filings. Reload the page in a minute to see it.

Not investment advice. Not affiliated with the U.S. SEC.